$6.70
-0.08 (-1.18%)
Amicus Therapeutics, Inc. (NASDAQ:FOLD)
CAPS Rating:
A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.
RSS Headlines
Fool UK